Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Health Canada approves Biogen Idec Inc 's Eloctate


Tuesday, 26 Aug 2014 08:00am EDT 

Biogen Idec Inc:Announces that Health Canada has approved ELOCTATE [Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein].For control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.(1).Says ELOCTATE is first recombinant hemophilia A therapy with prolonged circulation in body.It is only treatment for hemophilia A to reduce frequency of bleeding episodes via prophylactic regimens of either every three to five days, or once-weekly infusions.Says ELOCTATE offers people with hemophilia A potential to extend interval between prophylactic infusions.(1). 

Company Quote

316.46
0.4 +0.13%
10:31am EDT